Our dedicated medical team provides a personalized approach to care, carefully assessing each patients goals, medical history, and lifestyle to determine the most suitable and effective medication and treatment plan
Secondary 2026 analyses attribute retatrutide's reported hepatic fat reduction of up to 86% to this glucagon arm, though the primary MASLD endpoint paper is [unverified] in this dataset [1]
In phase III: Semaglutide 2.4 mg (STEP-1): nausea 44.2%, diarrhea 31.5%, vomiting 24.8% Tirzepatide 15 mg (SURMOUNT-1): nausea 29.2%, diarrhea 23.0%, constipation 16.8% Retatrutide 12 mg (TRIUMPH-1): nausea 37.2%, vomiting 22.0%, diarrhea 27.1% Key observation: tirzepatide shows the most favorable GI profile at equivalent dose, likely tied to the GIP component dampening GLP-1-mediated nausea signaling at the brainstem level
To read more on the FDA stance of unapproved drugs you can read this
Over time, this can lead to significant weight loss and contribute to your overall health and wellness goals
Stay hydrated with drinks such as water, fruit juices (unless they cause nausea), and broth Eat smaller, more frequent meals, instead of larger meals
